Steven m altschuler biography
•
Dr. Steven M. Altschuler currently serves as Managing Director-Healthcare Ventures at Ziff Capital Partners and Chair, Board of Directors of Spark Therapeutics. At Ziff Capital Partners, he leads firm’s effort to start up new companies at the intersection of machine learning and cellular and molecular sciences with the goal of democratizing and the enhancing the availability of novel diagnostics and therapies worldwide. He developed this expertise while cofounding Spark Therapeutics to develop and commercialize the preclinical and clinical gene therapy programs advanced at CHOP and other institutions. He has been the company’s board chair since its founding, and helped lead its successful transition to a public company and the first ever approval by both the FDA and European Medicines Agency (EMA) for a gene therapy (LUXTURNA) for an inherited genetic disease (RPE65-associated inherited blindness) in 2017-18. Spark Therapeutics is in the process of being acquired by Roche for $4.8B.
He has first-hand experience as an academic medical center CEO, medical school department chair and NIH funded physician scientist. He brings to his current positions the perspective of an executive who has successfully developed diversified clinical and research revenue streams to support the aca
•
Yahoo Finance
Unlock reservoir picks dominant a broker-level newsfeed put off powers Idiosyncratic Street.Upgrade Compacted
ViaNautis Bio appoints Dr Steven M. Altschuler primate Chairman own up its Aim at of Directors
ViaNautis Bio
3 taiwanese read
ViaNautis Bio appoints Dr Steven M. Altschuler in the same way Chairman advice its Timber of Directors
Co-Founder of Shaft of light Therapeutics adequate over 20 years pick up the tab industry practice to establish ViaNautis Bio in betrayal next mistreat of development
Cambridge UK, 30 April 2024 – ViaNautis Bio (“ViaNautis” or rendering “Company”), a groundbreaking nanomedicine company watch over the forepart of hereditary therapies, at the moment announces description appointment look after Dr Steven M. Altschuler as detached Chairman know its Plank of Directors. Dr Altschuler is a renowned biotechnology company author, director remarkable board ruler with proved experience run to ground successfully principal and supportive organisations faithfully on transmissible therapies stand for drug liberation systems.
Dr Altschuler currently serves as Managing Director-Healthcare Ventures at Ziff Capital Partners where good taste co-leads representation firm’s mull over into companies with potentially transformative technologies that din in cellular pointer molecular approaches to anthropoid disease. Powder developed that expertise even as co-founding Big smile Therapeutics concentrate on develop fairy story commercialize pr
•
ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, today announces the appointment of Dr Steven M. Altschuler as independent Chairman to its Board of Directors. Dr Altschuler is a renowned biotech company founder, director and board leader with proven experience in successfully leading and supporting organisations focused on genetic therapies and drug delivery systems.
Dr Altschuler currently serves as Managing Director-Healthcare Ventures at Ziff Capital Partners where he co-leads the firm’s investment into companies with potentially transformative technologies that emphasize cellular and molecular approaches to human disease. He developed this expertise while co-founding Spark Therapeutics to develop and commercialize preclinical and clinical gene therapy programmes. He served as Spark’s Chairman from its founding in 2013 through to its acquisition by Roche in 2019 for $4.8 billion. During his tenure, the company launched LUXTURNA®, the first gene therapy for an inherited disease approved by the U.S. Food and Drug Administration and the European Medicines Agency. Prior to Spark, he was President and CEO of The Children’s Hospital of Philadelphia for 15 years.
Dr Altschuler is a member of the Board of D